scispace - formally typeset
C

Chen Wang

Researcher at Mayo Clinic

Publications -  198
Citations -  15466

Chen Wang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Serous fluid. The author has an hindex of 33, co-authored 159 publications receiving 11490 citations. Previous affiliations of Chen Wang include Shanghai Jiao Tong University & University of Science and Technology of China.

Papers
More filters
Proceedings ArticleDOI

S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.

TL;DR: Significant molecular differences exist between ER+ BC that recur early vs. much later despite adjuvant TAM, and exploiting these differences will improve the understanding of involved signaling pathways, allow for the reliable prediction of early treatment failure, and guide use of novel therapeutics specifically directed at preventing E vs L recurrences on endocrine therapy.
Journal ArticleDOI

An innovative approach to predict technology evolution for the desoldering of printed circuit boards: A perspective from China and America

TL;DR: An innovative approach integrating Theory of Inventive Problem Solving (TRIZ) evolution theory and technology maturity mapping system is proposed to forecast the evolution trends of desoldering technology of waste printed circuit boards, predicting the law of energy conductivity and increasing the degree of idealisation.
Journal ArticleDOI

Modeling cancer clinical trials using HL7 FHIR to support downstream applications: A case study with colorectal cancer data.

TL;DR: CRFs can be considered as a proxy for representing information needs for their respective cancer types and can serve as a valuable resource for expanding existing standards to ensure they can comprehensively represent relevant clinical data without loss of granularity.
Journal ArticleDOI

Gene signature model for breast cancer risk prediction for women with sclerosing adenosis

TL;DR: The results provide the first demonstration that benign breast tissue contains transcriptional alterations that indicate risk of breast cancer development, demonstrating that essential precursor biomarkers of malignancy are present many years prior to cancer development.
Journal ArticleDOI

Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.

TL;DR: The largest cohort of RNA-seq from endometrioid OC to date, identified six hypermutated samples likely driven by POLE, which suggests the clinical need to screen for POLE driver mutations in endometioid OC, which can guide enrollment in immunotherapy clinical trials.